N
OMGA

Nuveen’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

Nuveen’s Portfolio OMGA Stock Details OMGA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-61,146
Closed -$223K – 3439
2024
Q1 		$223K Buy
61,146
+15,215
+33% +$58.3K ﹤0.01% 3163
2023
Q4 		$138K Hold
45,931
– – ﹤0.01% 3254
2023
Q3 		$98.8K Hold
45,931
– – ﹤0.01% 3123
2023
Q2 		$257K Buy
+45,931
New +$359K ﹤0.01% 3043
2022
Q2 		– Sell
-31,685
Closed -$219K – 3525
2022
Q1 		$219K Buy
+31,685
New +$323K ﹤0.01% 3174

Other funds holding OMGA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Nuveen's OMGA Position: Q2 2024 in Review

Nuveen sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q2 2024, closing a stake of 61,146 shares — an estimated $223K sold.

Nuveen first reported a position in OMGA in Q1 2022 and held it in 5 quarters. The position peaked at $257K in Q2 2023. 68 funds tracked by Wall St. Rank hold OMGA as of Q2 2024.

  • Nuveen reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Nuveen sold 61,146 Omega Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $223K.
  • Nuveen first reported a position in Omega Therapeutics, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
  • Nuveen's Omega Therapeutics, Inc. Common Stock position peaked at $257K in Q2 2023.
  • 68 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Nuveen's 13F filing for Q2 2024, filed 9 Aug 2024.